https://doi.org/10.48047/AFJBS.6.Si3.2024.3260-3269

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Skin Deep: Advances in Transdermal Drug Delivery Technology

Yogeishwar.S[1], Gayathri.H[2*], Damodharan.N[3]

[1]SRM College of Pharmacy, SRMIST, KattankulathurCampus, Tamil Nadu, India.
[2*]Assistant Professor, SRM College of Pharmacy, SRMIST, Kattankulathurcampus, Tamil Nadu
Email: gayathrh@srmist.edu.in
[3]Professor, SRM College of Pharmacy, SRMIST, Kattankulathur campus, Tamil Nadu, India

Article Info

Volume6, Issue Si3, July2024

Received: 01 June2024

Accepted: 29 June 2024

Published: 23 July 2024

doi:
10.48047/AFJBS.6.Si3.2024.3260-3269

ABSTRACT:

Transdermal drug delivery systems [TDDS] represent a significant advancement in the field of medicine, providing a non-invasive, controlled, and sustained method of drug administration. This paper explores the historical development, mechanisms, recent advancements, and future prospects of TDDS. The discussion covers various technologies, including patches, microneedles, and nanotechnology, highlighting their benefits, challenges, and potential impact on healthcare.

1. Introduction

Transdermal drug delivery systems are non-invasive and require no professional administration, making them a patient-friendly option. They improve patient adherence and reduce gastrointestinal side effects. Through avoiding the metabolic processes involved in oral delivery, Transdermal drug delivery enhances translocation, bioavailability, and efficacy. They also do away with the necessity for needles, which lowers medical waste and the infection risk connected to injections given by qualified medical personnel. The United States

approved the first transdermal patch for systemic distribution in 1979, providing a three-day patch for the treatment of motion sickness using scopolamine. Ten years later, nicotine patches were the first transdermal blockbuster, greatly increasing public and medical knowledge of transdermal delivery. There are currently 19 transdermal delivery systems on the market that can be used to deliver a variety of medications, including lidocaine, fentanyl, testosterone, and oestradiol. These consist of iontophoretic and ultrasonic pain relief devices, as well as combination patches for hormone replacement therapy and contraception [1-3].
The development of transdermal delivery techniques can be distinguished intothree generations. Medications that enter the skin at specified rates are examples of first-generation techniques. Second-generation techniques are improvements in the delivery of tiny molecules. Third-generation techniques enable the stratum corneum of the skin to be specifically permeable, enabling the transdermal delivery of macromolecules and vaccinations. By placing drugs more precisely within the body and frequently focusing on specific locations of action, this approach has the potential to improve both the therapeutic efficacy and safety of drugs [4-6].

Historical Development

The concept of transdermal drug delivery dates back to ancient times when substances were applied to the skin for therapeutic effects. However, the modern era of TDDS began in the 1970s with the development of the first transdermal patch for motion sickness. Since then, significant progress has been made, leading to a variety of transdermal systems for different therapeutic applications.[7-10]



Fig:1 Transdermal Drug Delivery system approach

When compared to conventional drug administration methods like oral intake or injection, transdermal drug delivery systems have the ability to lower the quantity and frequency of dosages needed for treatment because it enters the bloodstream through the skin without going through the digestive system. A few benefits of this precise drug distribution are decreased risk of systemic side effects and increased patient compliance. Additionally, drugs with limited therapeutic windows or those needing sustained release over an extended period

of time may benefit especially from Transdermal drug delivery systems[11-15].Microneedles offer a promising advancement in transdermal drug delivery, circumventing conventional limitations. Categorized by function, they can be solid, coated, hollow, dissolving, or hydrogel-forming. Polymers, chosen for their customizability, biocompatibility, and degradation properties, dominate microneedle fabrication. Biotech firms focus on developing microneedles for protein drug delivery to enhance efficacy. Challenges like drug size, hydrophilicity, poor absorption, and instability persist but ongoing research and technology advancements hold promise for delivering clinically significant medications.[16-19] Microneedles offer significant therapeutic advantages, providing precise and reproducible results with minimal inter-subject variability in bioavailability. However, they also pose limitations, including the potential for skin irritation or allergy, and the risk of microneedle tip breakage, which, if left in the skin, can lead to complications. These limitations, although rare, can be addressed through advanced material selection for microneedles. The primary goal of this technology is to create larger transport pathways, disrupting the stratum corneum to enhance permeability for larger molecules, bridging the gap between molecular dimensions and traditional hypodermic needle holes.[20-24]

Skin and Drug Permeations

Delivering drugs systemically through unbroken skin is the aim of transdermal drug delivery systems. It is essential to study the biochemical and structural characteristics of human skin, which serve as barriers governing the entry of drugs into the body, in order to comprehend this process.The stratum corneum, dermis, and hypodermis are the three primary layers of human skin, which forms a strong barrier against penetration.

The outermost layer, known as the Stratum corneum, is roughly 10μm thick and functions as a barrier because of its high protein [79–90%] and lipid [5–15%] concentration. The thickness is dependent on the number of layers and the thickness of the cells.[25-28]Dermis is Mostly made up of connective tissues, the dermis has a thickness of 3–5 mm. It helps eliminate harmful materials from the body, maintains body temperature, and gives the skin oxygen and nourishment. Hypodermis is an Supporting the dermal and epidermal layers, this layer stores fat tissues. Since medications must pass through all three layers in order to enter the systemic circulation, it is also essential to transdermal drug delivery.[29-32]The reticular dermis is covered by subcutaneous tissue, which varies in thickness by several millimetres. It contains nerves, lymphatics, and blood vessels in addition to loose connective tissue and fat micro lobules. Due to the distinct physiological makeup of this layer, there is a chance to transport therapeutic substances across the skin to treat diseases. Drugs administered transdermally are more easily distributed due to the skin's robust link with the rest of the body, which is facilitated by the skin's numerous blood and lymphatic capillaries. The skin barrier is essential for defending the human body from infections, even with this potential. However, this barrier also presents a significant barrier to successful transdermal drugs administration, as it inhibits the drugs' potential to pass through the skin.[33-35]

Fig:2 Drug penetration pathway

Route of Drug Penetrations

A pharmacological molecule can pass through the intact stratum corneum [SC] in three primary ways: through the intercellular lipid domains, through skin appendages, or by a transcellular pathway. [36-38]

1.Appendageal Route: Permeation through sweat glands and hair follicles with related sebaceous glands is what's commonly referred to as a "shunt route." A different route for drugs delivery is provided by skin appendages, which offer a continuous conduit directly over the SC barrier.

2. Trans-cellular Route: substances enter through corneocytes, which give hydrophilic substances an aqueous environment to pass through because they contain highly hydrated keratin. Diffusion through intercellular lipids and partitioning into keratin bricks are necessary for this mechanism.

3.Intercellular Route: Involves drug diffusion through the continuous lipid matrix. This path is challenging due to the tortuous nature of the corneocyte arrangement and the structured bilayers of the intercellular domain. It's considered the most common path for small, uncharged molecules penetrating the skin

Advantages of Transdermal Drug Delivery:

Improved Patient Compliance: TDDS eliminates the need for frequent dosing, reducing the likelihood of missed doses and simplifying complex medication regimens. Patients, particularly those requiring long-term therapy, benefit from the convenience and ease of application.

Stable Drug Levels: By providing sustained release of medication, TDDS helps maintain stable plasma concentrations, minimizing fluctuations commonly associated with oral medications. This steady state improves efficacy while reducing adverse effects.

Reduced Side Effects: Transdermal delivery bypasses the gastrointestinal system, thereby reducing the risk of gastrointestinal irritation and other side effects associated with oral

medications. Additionally, the controlled release of drugs can mitigate peak plasma concentrations, lowering the incidence of dose-related adverse reactions.

Non-Invasive and Painless: Unlike injections or invasive procedures, transdermal patches offer a painless and non-invasive route of drug administration. This feature is particularly advantageous for pediatric, geriatric, and needle-phobic patients.

Targeted Delivery: TDDS allows for localized drug delivery to specific areas of the body, minimizing systemic exposure and maximizing therapeutic efficacy. This targeted approach is beneficial in treating conditions such as chronic pain, inflammation, and dermatological disorders.

Applications of Transdermal Drug Delivery:
The versatility of transdermal delivery has led to its widespread adoption across various medical specialties:

Pain Management: Transdermal patches are commonly used to deliver analgesic medications for chronic pain conditions, offering sustained relief without the need for frequent dosing.
Hormone Replacement Therapy: Transdermal patches and gels are utilized for hormone replacement in conditions such as menopause and hypogonadism, ensuring controlled release and systemic absorption.

Cardiovascular Disorders: Nitroglycerin patches are employed to manage angina, providing continuous vasodilation to alleviate symptoms.

Neurological Disorders: Transdermal formulations of medications such as rivastigmine are used in the treatment of Alzheimer's disease, offering a convenient alternative to oral administration.

Future Directions and Challenges:
While transdermal drug delivery has revolutionized pharmaceuticals, ongoing research aims to address existing limitations and explore new possibilities. Challenges such as limited drug permeability, skin irritation, and the need for specialized formulation technologies persist. However, advancements in nanotechnology, microfabrication, and novel drug carriers hold promise for overcoming these hurdles.
The future of transdermal drug delivery lies in personalized medicine, where tailored formulations and delivery systems cater to individual patient needs. From wearable devices to microneedle arrays, innovative approaches are poised to further enhance the efficacy, safety, and convenience of transdermal therapy.
Transdermal drug delivery systems [TDDS] have evolved significantly, incorporating various novel technologies to improve drug delivery efficiency, enhance patient compliance, and expand the range of drugs that can be administered through the skin. Some notable advancements in transdermal drug delivery systems include:

Microneedle Technology: Microneedles are tiny needles typically ranging from tens to hundreds of micrometers in length. They create micropores in the skin, facilitating the delivery of drugs into deeper skin layers or directly into the bloodstream. Microneedle patches offer a minimally invasive and painless alternative to conventional needles for drug delivery.

Nanotechnology: Nanoparticles can encapsulate drugs and enhance their permeation through the skin. Various nanoparticle formulations, such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles, have been explored for transdermal drug delivery. These nanoparticles can protect the drug from degradation, control release kinetics, and improve skin penetration.

Hydrogel-based Systems: Hydrogels are three-dimensional networks of hydrophilic polymers capable of holding large amounts of water. They can serve as drug reservoirs, releasing drugs in a controlled manner upon contact with the skin. Hydrogel-based transdermal patches offer enhanced adhesion, flexibility, and prolonged drug release.

Iontophoresis and Electroporation: These techniques utilize electrical currents to enhance drug permeation through the skin. Iontophoresis involves the application of a low-level electric current to drive charged molecules across the skin barrier, while electroporation creates temporary nanopores in the skin, allowing for enhanced drug penetration.

Chemical Penetration Enhancers: Certain chemicals, such as fatty acids, terpenes, and surfactants, can disrupt the skin barrier and enhance drug permeation. These penetration enhancers are often incorporated into transdermal formulations to improve drug absorption rates.

3D Printing: 3D printing technology enables the fabrication of customized transdermal patches with precise drug dosage and release profiles. This approach allows for personalized medicine and the incorporation of multiple drugs or therapeutic agents into a single patch.
These novel drug delivery systems hold promise for improving the efficacy, safety, and convenience of transdermal drug administration across various therapeutic areas, including pain management, hormone replacement therapy, and cardiovascular disease. However, challenges such as skin irritation, regulatory hurdles, and scalability need to be addressed for widespread clinical adoption.

Transferosomes are a type of novel drug delivery system designed to enhance the transdermal delivery of drugs, particularly those with low skin permeability. They belong to the category of elastic vesicles, which are lipid-based vesicular carriers capable of encapsulating both hydrophilic and lipophilic drugs.
Transferosomes are composed of phospholipids and edge activators, such as surfactants or bile s*alts, which impart elasticity to the vesicles. This elasticity enables transferosomes to deform and squeeze through pores in the stratum corneum, the outermost layer of the skin, thereby facilitating penetration into deeper skin layers and enhancing drug absorption.
The unique structure of transferosomes allows them to adapt to the complex and dynamic environment of the skin, including its irregular topography and lipid composition. This property enables efficient drug delivery across the skin barrier, bypassing the limitations associated with conventional transdermal delivery systems.
Transferosomes offer several advantages for transdermal drug delivery, including:

Enhanced Skin Penetration: The elastic nature of transferosomes enables them to penetrate the skin more efficiently compared to conventional liposomes or nanoparticles.

Improved Drug Bioavailability: By enhancing drug permeation through the skin, transferosomes can increase drug bioavailability and therapeutic efficacy while minimizing systemic side effects.

Versatile Drug Loading: Transferosomes can encapsulate a wide range of drugs, including hydrophilic, lipophilic, and amphiphilic compounds, making them suitable for delivering diverse therapeutic agents.

Biocompatibility: Transferosomes are composed of biocompatible phospholipids and edge activators, minimizing the risk of skin irritation or allergic reactions.

Targeted Delivery: Transferosomes can be surface-modified or functionalized with ligands to achieve targeted drug delivery to specific skin layers or cell types.
Transferosomes hold promise for various applications, including the delivery of drugs for dermatological disorders, local anesthesia, vaccination, and cosmetic formulations. However, *challenges such as stability during storage, scalability of production, and regulatory approval need to be addressed for their widespread clinical use. Ongoing research is focused on optimizing transferosome formulations and exploring their potential in personalized medicine and combination therapy.

Transferosomes are a type of lipid-based vesicle designed to enhance the transdermal delivery of drugs and therapeutic agents. They're essentially composed of phospholipids and edge activators, which make them highly adaptable for traversing the skin's lipid barrier.
As for recent trends, there's been a significant focus on optimizing transferosome formulations to improve drug delivery efficiency, stability, and targeting. Here are a few notable trends:

Nanotechnology Integration: With advancements in nanotechnology, researchers are exploring ways to incorporate nanoparticles into transferosome formulations. This integration aims to enhance drug loading capacity, stability, and targeting capabilities.

Targeted Delivery: Transferosomes can be engineered to target specific cells or tissues, minimizing off-target effects and improving therapeutic outcomes. Recent trends involve the development of ligand-conjugated transferosomes for targeted delivery to tumors, inflamed tissues, or specific cell types.

Co-delivery Systems: Combining multiple drugs or therapeutic agents in a single transferosome formulation is gaining attention. Co-delivery systems offer synergistic effects, improved patient compliance, and enhanced therapeutic efficacy. Researchers are investigating various strategies to co-encapsulate drugs with different physicochemical properties within transferosomes.

Modified Edge Activators: Edge activators play a crucial role in destabilizing the lipid bilayer structure of transferosomes, facilitating drug release and skin penetration. Recent trends involve the exploration of novel edge activators or modifications to existing ones to improve transferosome stability, drug loading efficiency, and skin permeation.

Functionalization for Enhanced Penetration: Surface functionalization of transferosomes with permeation enhancers or penetration enhancer peptides is an emerging trend. These

modifications aim to further improve skin penetration and drug delivery efficiency, especially for macromolecules or hydrophilic drugs that face challenges in transdermal delivery.

Biocompatible Materials: There's a growing emphasis on utilizing biocompatible and biodegradable materials in transferosome formulations to enhance safety and reduce potential adverse effects. Researchers are exploring natural lipid sources and biodegradable polymers as alternatives to synthetic materials.

Combination with Physical Enhancement Techniques: Combining transferosomes with physical enhancement techniques such as sonophoresis, microneedle arrays, or electroporation is gaining traction. These combined approaches can further enhance transdermal drug delivery by overcoming skin barriers and improving transferosome penetration.

2. Conclusion

Transdermal drug delivery systems represent a paradigm shift in medication administration, offering a safe, convenient, and effective alternative to traditional routes. With their ability to provide controlled release, targeted therapy, and improved patient adherence, TDDS has transformed the treatment landscape across a spectrum of medical conditions. As research continues to push the boundaries of innovation, the future holds immense potential for advancing the field of transdermal drug delivery and unlocking new possibilities in patient care.

3. Reference

1. Donatella P, Piyush S, Massimo F, Mauro F. Drug delivery systems. Encyclopedia of Medical Devices and Instrumentation. 2009; 2[8]: 437-95. doi:10.1002/0471732877.emd274
2. John MW,Kewal KJ. Drug delivery systems. Methods in molecular biology. 2008;437:1-50.doi: 10.1007/978-1-59745-210-6_1
3. Prabhakar D, Sreekanth J, Jayaveera KN. Transdermal drug delivery patches: a review. Journal of Drug Delivery and Therapeutics. 2013; 3[4]: 213-21. http://jddtonline.info.
4. Sanjay B, Bigail W, Brigitta B. Transdermal drug delivery in pain management. Advance Access publication. Continuing Education in Anaesthesia, Critical Care and Pain. 2011; 11[2]: 39-43. doi:10.1093/bjaceaccp/mkq054
5. Woo YJ. Mina K. Hye EC. Ki SK. Recent advances in transdermal drug delivery systems: a review. Biomaterials Research. 2021; 25[24]: 1-15. https://doi.org/10.1186/s40824-021-00226-6
6. Nidhi S. A brief review on transdermal patches. Organic and Medicinal Chemistry International Journal Review Article. 2018; 7[2]: 58-62. doi: 10.19080/OMCIJ.2018.07.555707
7. Kuick R. Global transdermal patch market, dosage, price and clinical trials insight 2028. Advance Access publication. 2022.
8. Mathews L. Roy A. Management of pain using transdermal patches – A review. Asian J Pharmaceutical Clin Res. 2016; 9[6]: 32-5. doi: https://doi.org/10.22159/ajpcr.2016.v9i6.13775
9. Durand C, Alhammad A, Willett KC. Practical considerations for optional transdermal drug delivery. Am J Health Syst Pharm. 2012; 69[2]: 116-24. doi: 10.2146/ajhp110158.

10. Yuji S, Kenji K. Transdermal drug delivery [TDD] in pathology and treatment. Integrated nano-biomechanics. Science direct, Edited by Takami Yamaguchi, Takuji Ishikawa and Yohsuke Imai. 2018.
11. Rajesh M, Kishor D. A Review on Transdermal Drug Delivery System. Research J. Science and Tech. 2011; 3[5]: 227-31.
12. Sai VK, Saikrishna P. Effect of Casting Solvent and Polymer on Permeability of Glipizide through Rate Controlling Membrane for Transdermal Use. Research J. Science and Tech. 2011; 3[4]: 180-3.
13. Nandkumar R, Kadam MM, Rokade. Transdermal Drug Delivery System. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13[2]: 125-9. doi: 10.52711/2231-5659.2023.00023
14. Nagadev C, Durga SR, Venkatesh P, Hepcykalarani D, Prema R. A Review on Transdermal Drug Delivery Systems. Asian J. Res. Pharm. Sci. 2020; 10[2]: 109-14. doi: 10.5958/2231-5659.2020.00021.1
15. Washington C, Washington N. Drug delivery to the skin. In: Physiological Pharmaceutics, Biological Barriers to drug absorption. A John Wiley and Sons, Inc., Publication. Edited by Heather A.E. Benson, Adam C. Watkinson. 2012.
16. Lisi DM. OTC Transdermal analgesic patches in pain management. US Pharm. 2019; 44[3]: 15-21.
17. Ismail H, Ravikumar, Narayanaswamy VB, Injamamul H, Mohibul H. Design and Evaluation of Transdermal Patches Containing Risperidone. Asian J. Res. Pharm. Sci. 2016; 6[4]: 208-22. doi: 10.5958/2231-5659.2016.00030.8
18. Mithun B, Tamizharasi S, Sivakumar T. Challenges Facing Transdermal Drug Delivery Systems: A Conceptual Approach. Research J. Science and Tech. 2012; 4[5]: 213-19.
19. Rakesh PP, Grishma P, Hitesh P, Ashok B. Formulation and Evaluation of Transdermal Patch of Aceclofenac. Research J. Pharma. Dosage Forms and Tech. 2009; 1[2]: 108-15.
20. Nikhil P, Chetan P, Savan V, Prajapati ST, Patel CN. Recent Advances in Transdermal Drug Delivery System. Research J. Pharma. Dosage Forms and Tech. 2010; 2[2]: 113-19.
21. Saikumar Y., Saikishore V., Pavani K., Sairam D.T. Sindhura A. Role of Penetration Enhancers in Transdermal Drug Delivery System. Research J. Pharma. Dosage Forms and Tech. 2012; 4[6]: 300-8.
22. G. Vasavi, P. Naga Haritha, B. Chandrashekar. Formulation Development and In vitro Evaluation of Transdermal Patches of Tramadol HCl. Asian J. Res. Pharm. Sci. 2018; 8[3]: 123-9. doi: 10.5958/2231-5659.2018.00021.8
23. Dipen P, Sunita A, Chaudhary BP, Nikunj B.Transdermal drug delivery system: A review. The Pharma Innovation International Journal. 2012; 1[4]: 66-75. Available at www.thepharmajournal.com.
24. Michael NP, Yogeshvar NK, Michael H, Michael SR. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015; 172[9]: 2179-209. doi: 10.1111/bph.13059
25. Lyn M, Richard S. Transdermal drug delivery: principles and opioid therapy, continuing education in anaesthesia critical care and pain. oxford Acadamic Journals. 2007; 7[5]: 171-9. https://doi.org/10.1093/bjaceaccp/mkm033
26. Manisha S,ShivakumarHN,Prajila A. Formulation and evaluation of transdermal patch of rabeprazole sodium. Journal of Reports in Pharmaceutical Sciences. 2021; 10[2]: 240-6. doi: 10.4103/jrptps.JRPTPS_126_20

27. Othman A. Al Hi, Haji MSK, Muhammad S, Mosab A, Shakeel I, Abdul H. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharm. 2019; 69[2]: 197-215. doi: 10.2478/acph-2019-0016.
28. Francesco C, Paola M, Antonella C, Leila, Stefania P, Luisa M. Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen. Eur J Pharm Biopharm. 2005; 60[1]: 61-8. doi: 10.1016/j.ejpb.2005.02.001
29. Khwaja S. Transdermal Patches. Pharmatutor. 2012.
30. Haji MSK, Muhammad S, Mosab A, Shakeel I, Abdul H. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica. 2018; 69[1]: 1-19. https://doi.org/10.2478/acph-2019-0016
31. Roy N, Agrawal M, Chaudhary S, Tirkey V, Dhwah A, Mishra N. Review article on permeation enhancers: a major breakthrough in drug delivery technology. Int J Pharmaceutical Sci and Res. 2017; 8[3]: 1001–11. doi: 10.13040/IJPSR.0975-8232.8[3].1001-11
32. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system [TDDS] adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006; 64[1]: 1-8. doi: 10.1016/j.ejpb.2006.03.009.
33. Kathe K, Kathpolia H. Film forming systems for topical and transdermal drug delivery. Asian J Pharm Sci. 2017; 12[6]: 487-97. doi: 10.1016/j.ajps.2017.07.004
34. Pawan J, Anju J, Lalita D, Yashpal S, Rajiv S. A review on transdermal patches the pharma research, a journal, The Pharma Research. 2010; 3: 139-49.
35. Farzaneh S, Beom SK. Recent advances in polymeric transdermal drug delivery systems. Journal of Controlled Release. 2022;[341]:132-46. https://doi.org/10.1016/j.jconrel.202 1.11.025
36. Gayathri H, S. Sangeetha, N. Damodharan. Formulation and Ex-vivo Permeation Study of Tamoxifen Citrate Loaded Transfersomal Gel. International Journal of Pharmaceutical Quality Assurance. 2022;13[4]:354-357.
37. Gayathri, H., & Sangeetha, S. [2022]. Design and development of tofacitinib citrate loaded transferosomal gel for skin cancer by box-Behnken design- doe approach. International Journal of Health Sciences, 6[S6], 3119–3140. https://doi.org/10.53730/ijhs.v6nS6.10118
38. Gayathri H1*, Dr.S.Sangeetha. Pharmaceutical Development Of Methotrexate Loaded Transferosomal Gel For Skin Cancer By Doe Approach Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Special Issue 5 ¦ 2022